Karyopharm Therapeutics | KPTI - Ebit

Aktienkurs
9.36
Täglich Wechseln
-0.05 -0.53%
Monatlich
29.82%
Jährlich
53.19%
Q2 Prognose
8.59




Ebit Veränderung Datum
AbbVie USD 4.73B 1.08B 2026-03
Abbott USD 1.85B 684M 2026-03
Amgen USD 3.83B 130M 2026-03
AstraZeneca USD 7.11B 4.14B 2026-03
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Bristol-Myers Squibb USD 3.56B 90M 2026-03
Eli Lilly USD 9.78B 792M 2026-03
Enanta Pharmaceuticals USD -23.54M 6.31M 2024-12
GlaxoSmithKline GBP 2.29B 856M 2026-03
Incyte USD 344.17M 39.71M 2026-03
J&J USD 6.62B 1.51B 2026-03
Karyopharm Therapeutics USD -17.84M 8.44M 2025-12
MacroGenics USD -12.1M 32.26M 2025-12
Merck USD -1.88B 8.12B 2026-03
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Novartis USD 4.18B 118M 2026-03
Novartis USD 4.06B 413M 2025-12
Pfizer USD 4.99B 340M 2026-03
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Roche Holding CHF 9.56B 2.1B 2025-12
Takeda JPY 257.49B 568.56B 2025-12
Tectonic Therapeutic USD -21.52M 374K 2025-12
TG Therapeutics USD 50.49M 21.13M 2025-12
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
Xencor USD -53.63M 6.11M 2025-12